vanzacaftor-tezacaftor-deutivacaftor

Selected indexed studies

• Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. (Lancet Respir Med, 2025) [PMID:39756424]
• Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. (Lancet Respir Med, 2025) [PMID:39756425]
• Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. (Lancet Respir Med, 2023) [PMID:36842446]

_Worker-drafted node — pending editorial review._